Program
Extended Release Torsemide Tablets
Also written as “Extended release torsemide 24mg tablet” and “Extended release torsemide”.
Its studies are mostly in Heart Failure, led by Sarfez Pharmaceuticals.
Furthest: phase 4, since May 16, 20253 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sarfez Pharmaceuticals | 30 open or running | phase 4since May 16, 2025 | Dec 11, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 11, 2023First study: phase 2 study in Heart FailureFirst studyNCT06176794 · United States
- Jan 4, 2024Phase 2 study in Heart FailureNCT06206512 · 24 enrolled · United States
- May 16, 2025Phase 4 study in Heart FailureNCT06995144 · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06995144Heart Failure · United States | 4 | Withdrawn | Sep 16, 2026 | 0 |
| NCT06206512Heart Failure · United States | 2 | Completed | Nov 17, 2025 | 24 |
| NCT06176794Heart Failure · United States | 2 | Withdrawn | Mar 25, 2025 | 0 |
How it is read
Names in the registry
- “Extended Release Torsemide Tablets”, 1 entry
- “Extended release torsemide 24mg tablet”, 1 entry
- “Extended release torsemide”, 1 entry
Conditions, from the studies’ own filings
- Heart Failure, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.